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Abstract: Fucoidans, sulfated polysaccharides extracted from brown algae, are marine products with
the potential to modulate bone formation and vascularization processes. The bioactivity and safety
of fucoidans are highly associated with their chemical structure, which may vary with algae species
and extraction method. Thus, in depth evaluation of fucoidan extracts in terms of endotoxin content,
cytotoxicity, and their detailed molecular biological impact on the individual cell types in bone is
needed. In this study, we characterized fucoidan extracts from three different Fucus species including
Fucus vesiculosus (Fv), Fucus serratus (Fs), and Fucus distichus subsp. evanescens (Fe) for their chemical
features, endotoxin content, cytotoxicity, and bioactive effects on human outgrowth endothelial
cells (OEC) and human mesenchymal stem cells (MSC) as in vitro models for bone function and
vascularization. Extracts contained mainly high molecular weight (HMW) fucoidans and were free
of endotoxins that may cause inflammation or influence vascularization. OEC tolerated fucoidan
concentrations up to 200 µg/mL, and no indication of cytotoxicity was observed. The inflammatory
response, however, investigated by real-time PCR (RT-PCR) and enzyme-linked immunosorbent
assay (ELISA) and endothelial barrier assessed by impedance measurement differed for the individual
extracts. MSC in comparison with endothelial cells were more sensitive to fucoidans and showed
partly reduced metabolic activity and proliferation at higher doses of fucoidans. Further results for
MSC indicated impaired osteogenic functions in alkaline phosphatase and calcification assays. All
tested extracts consistently lowered important molecular mediators involved in angiogenesis, such a
VEGF (vascular endothelial growth factor), ANG-1 (angiopoietin 1), and ANG-2 (angiopoietin 2), as
indicated by RT-PCR and ELISA. This was associated with antiangiogenic effects at the functional
level using selected extracts in co-culture models to mimic bone vascularization processes during
bone regeneration or osteosarcoma.
Keywords: fucoidan; mesenchymal stem cells (MSC); outgrowth endothelial cells (OEC); angiogene-
sis; bone vascularization
1. Introduction
Fucoidans, sulfated polysaccharides derived from brown algae, have been reported
to influence a series of physiological key processes such as inflammation [1–3], vascular-
ization [4,5], as well as the recruitment of stem cells [6]. All these mentioned biological
processes play a fundamental role for a variety of different tissues or diseases and are of
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particular interest for applications in bone health, ranging from the maintenance of func-
tional bone tissue and enhancement of bone regeneration and repair, up to the treatment of
bone tumors, such as osteosarcoma [7–9].
In most cases, extracts comprise a heterogeneous composition with large variations
in monosaccharide composition, molecular weight, sulfation degree, etc. [10,11]. Accord-
ingly, the structure–function relationship for fucoidans often remains unclear, thus limiting
their suitability as a biomedical compound. One key prerequisite for using fucoidans in
biomedical applications is to develop purified and standardized extracts with well-defined
chemical characteristics [12]. In addition to the production of extracts with distinct phys-
ical or chemical properties, the evaluation of the tissue- or cell type-specific effects is an
important strategy to ensure biological safety by selecting non-toxic but bio-functional
doses [13,14]. Further, tests of fucoidans in selected cell models providing controlled physi-
ological conditions can contribute to a better understanding of how fucoidans modulate
processes, such as bone formation or vascularization. In addition, such tests enable identifi-
cation of the associated molecular mediators influenced by fucoidan extracts. In previous
reports, we have demonstrated biological effects in in vitro models for bone and associ-
ated vascularization processes using a crude fucoidan extract from Fucus vesiculosus [4]
or fractionated extracts from Fucus distichus subsp. evanescence [15]. Before biomedical
use of fucoidans, complex testing procedures are necessary. This is a challenging task,
especially when considering the large number of extracts that can be gained from the
different species of brown algae, as well as from different extraction methods or processing
technologies, such as fractionation [10,16,17]. In this context, a detailed characterization of
the molecular biological effects of fucoidans in the target cells will support the selection of
extracts with the best biomedical effect for the envisioned therapeutic aim, contribute to
their biological safety, and enable definition of structural and functional relationships at
cellular and molecular levels.
In this study, using a variety of characterization methods in in vitro models, we
prepared and tested fucoidan extracts from different Fucus species and compared them in
terms of their chemical characteristics, endotoxin content, and their biological impact on
endothelial cells and bone-forming mesenchymal stem cells.
2. Results
2.1. Chemical Characterization of Fucoidan Extracts
Analysis of the monosaccharide composition by acetylation analysis of the six fu-
coidans from F. vesiculosus (Fv), F. distichus subsp. Evanescens (Fe), and Fucus serratus (Fs)
revealed that Fv3, Fe, and Fs1 had the highest fucose content (above 75%) along with the
highest degrees of sulfation (DS), whereas the other three extracts had a fucose content
below 60%. In addition, Fv1 and Fs2 contained a considerable amount of glucose (Table 1),
which probably represents co-extracted ß-1,3-glucans of brown algae.
The molecular mass (MW) of the fucoidans largely differed from 84 kDa (Fe) to 730 kDa
(Fv2). The MW and size parameter of the samples are summarized in Table 1. Further, the
MW distribution plots of the fucoidans and MW ranges of three weight fractions (≤20%,
20–80%, ≥80% (m/m)) of different fucoidans are included as Supplementary Materials
(Table S1, Figures S1 and S2). These data illustrate that all the fucoidans extracts represent
highly polydisperse mixtures; even the MW of Fe with the lowest polydispersity ranged
from 22 kDa to 403 kDa.
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Table 1. Composition of neutral monosaccharides (Fuc (fucose), Xyl (xylose) Gal, (galactose), Glc
(glucose)), degree of sulfation (DS), protein content, molecular mass, and rms radius of the extracted
fucoidans from fucus vesiculosus (Fv), fucus distichus subsp. evanescens (Fe)and fucus serratus (Fs)
Monosaccharide







(nm)Fuc Xyl Gal Glc
Fv1 50.2 9.5 7.9 27.7 0.28 1.88 449 35
Fv2 57.7 18.5 13.2 2.9 0.26 1.08 730 33
Fv3 81.4 8.5 6.3 0.7 0.35 0.33 173 24
Fe 76.7 9.8 5.7 0.0 0.41 2.18 84 21
Fs1 76.2 6.5 3.3 11.2 0.61 0.52 272 41
Fs2 56.1 4.1 5.0 32.6 0.32 0.51 172 36
a Determined according to the method of Blakeney et al. [18]. b Averaged number of sulfate groups per
monosaccharide, calculated as -SO3Na residues from sulfur content determined by elemental analysis. c The
content of protein was calculated by elemental analysis (nitrogen (%)).
2.2. Endotoxicity
Before characterizing the cytotoxicity and biological activity, the endotoxin content in
the extracts was determined by EndoLISA to exclude influences by endotoxins that might
further cause endothelial cell activation and severe inflammatory responses. As depicted
in Table 2, endotoxin levels were below critical values for all tested extracts in this study.
Table 2. Endotoxicity of fucoidan extracts and heparin determined by EndoLISA® kit.
Fucoidan Extracts/Heparin Shortage Endotoxicity (EU/mL)
Heparin (for physico-chemical analysis, Y0001282) Hep. 0.0778
Fucoidan from Fucus vesiculosus crude (Fvc, Sigma, F5631-1G) Fvc 0.0746







2.3. Effect of Fucus Extracts on Metabolic Activity and Cytotoxicity in Endothelial Cells
Independent from Fucus species and the tested concentration (1 to 200 µg/mL)
(Figure 1), no cytotoxic effects were observed for tested extracts in human microvascular
endothelial cells from the peripheral blood (OEC). Using lactate dehydrogenase (LDH)
assessment as an indicator for cell membrane damage, all the tested extracts resulted in
reduced LDH levels observed at both investigated time points (72 h, 168 h). Remarkably,
in contrast to the other test compounds and to the results on day 7, Fv1 and Fv2, the
two fucoidans with the highest MW but lowest DS, significantly improved the metabolic
activity on day 3. In agreement with the test principles of MTS and LDH, assay data
resulted in complementary results for metabolic activity and cytotoxicity.
2.4. Impact of Fucus Extracts on the Endothelial Barrier
Morphological assessment of OEC by immunofluorescence for VE-cadherin after
seven days of treatment (100 µg/mL) indicated partly a rearrangement of the cell layer and
the endothelial cell–cell contact mediated barrier. This effect was most prominent for the
commercially available crude fucoidan from Fucus vesiculosus (Figure 2). Morphological
assessment further indicated to some extent effects on the cell–cell contacts for other Fucus
vesiculosus extracts (Figure 2, arrow); these, however, were much less evident.
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Figure 1. Cell metabolic activity of outgrowth endothelial cells (OECs) determined by MTS assay at (a) 72 h and (b) 168 h
and cytotoxicity for OECs determined by lactate dehydrogenase (LDH) at (c) 72 h and (d) 168 h after treated with fucoidan
extracts and heparin at different concentrations of 1, 10, 50, 100, and 200 µg/mL. Two-way ANOVA, * p < 0.05, ** p < 0.01,
*** p < 0.001, **** p < 0.0001, n = 3.
To quantify potential effects of the tested fucoidans on the endothelial barrier, we
performed electric impedance measurements using an electrical cell-substrate impedance
sensing (ECIS) system (Figure 3). For this, OEC were grown until the impedance reached
a stable level as an indicator of a stable and tight endothelial cell layer. Then, OEC were
treated with the fucoidan extracts for a further seven days. Depicted impedance values were
normalized to measured values on day 0 (100%). In accordance with the morphological
observation in Figure 2, treatment with the crude fucoidan from Fucus vesiculosus resulted
in a significant reduction of the impedance on day 5. A similar effect was observed for Fv1
and Fv2, although here the reduction of the impedance showed only a tentative trend. In
contrast, the barrier of OEC after treatment with Fs1, Fs2, and Fe remained stable, and no
impedance reduction was observed.
2.5. Effects of Fucus Extracts on Endothelial Activation and Inflammation
To study the impact of fucoidan extracts (100 µg/mL) on inflammatory and angiogenic
endothelial cell activation [19,20], the secretion of associated inflammatory mediators
(interleukin-6 IL-6 and intracellular adhesion molecule-1(ICAM-1)) and the proangiogenic
molecule ANG-2 produced by endothelial cells [21] was determined by ELISA (Figure 4a–c).
In addition, we performed real-time PCR for gene expression of IL-6, ICAM-1, and vascular
cells adhesion molecule-1 (VCAM-1) (Figure S3) but we focus here on the protein level due
to the higher physiological relevance. For protein assessment, all samples were harvested
after seven days. Only Fv2 treatment resulted in a significant increase of IL-6 compared
with the control, indicating an inflammatory reaction of the endothelial cells by Fv2, which
was further underlined by a tentative increase in soluble ICAM-1. A similar but not
significant increase of IL-6 was observed for Fv1. Further, the results indicate a significant
reduction of angiopoietin 2 (ANG-2) for most extracts except for Fvp and Fe, indicating a
reduction of this proangiogenic molecule produced by endothelial cells.
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Figure 2. Confocal laser scanning microscopy of OEC mono-cultures on day 7 for (a,b) controls and
treatment of 100 µg/mL fucoidan extracts: (c) Fvc, (d) Fvp, (e) Fv1, (f) Fv2, (g) Fv3, (h) Fs1, (i) Fs2
and (j) Fe. VE-cadherin is depicted in green. The scale bar represents 100 µm.
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Figure 3. Cell barrier characterized by electrical cell-substrate impedance sensing (ECIS) for OEC mono-culture in response
to fucoidan and heparin at 100 µg/mL treatment. Two-way ANOVA, * p < 0.05, n = 3.
Figure 4. The protein level of inflammatory molecules (a) IL-6, (b) soluble ICAM-1 and (c) angiopoietin 2 (ANG-2) in the
supernatant determined by ELISA for OEC treated with 100 µg/mL fucoidan. One-way ANOVA, * p < 0.05, ** p < 0.01,
n = 3.
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2.6. Effect of Fucus Extracts on Metabolic Activity and Cytotoxicity in Human Mesenchymal
Stem Cells
The effects of Fucus extracts on the metabolic activity and cytotoxicity for MSCs
were tested using concentrations from 1 up to 200 µg/mL. In contrast to the results for
endothelial cells, treatment with Fvc, Fvp, Fv1, Fv2, and Fv3 at concentrations higher
than 10 µg/mL reduced the metabolic activity of MSC at both investigated time points
(Figure 5a,b). For treatment with Fs1, only high concentrations of 100 and 200 µg/mL
indicated a reduced metabolic activity after three days of incubation, while Fs2 and Fe
extracts had no negative influence on the metabolic activity of MSC. Because LDH values
as an indicator of membrane integrity (Figure 5c,d) were not significantly decreased, we
assume that the decreased values in the MTS assay refer to a decrease in metabolic activity
or proliferation rather than a cytotoxic effect.
Figure 5. Cell metabolic activity of mesenchymal stem cells (MSCs) determined by MTS assay at (a) 72 h and (b) 168 h
and cytotoxicity for MSCs determined by LDH at (c) 72 h and (d) 168 h after treated with fucoidan extracts and heparin at
different concentrations of 1, 10, 50, 100, and 200 µg/mL. Two-way ANOVA, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001,
n = 3.
To clarify, whether the MTS assay results reflect only a reduction of the metabolic
activity or indicated a reduced proliferation, we investigated the effects using DNA quan-
tification as a direct indicator of cellular proliferation at a concentration of 1 and 10 µg/mL.
Results for DNA quantification at day 7 as depicted in Figure 6a,b did not show significant
effects on MSC proliferation for the lower concentrations 1 and 10 µg/mL, although these
concentrations reduced partly the metabolic activity. Nevertheless, the MSC seeding den-
sity in these experiments was relatively high, potentially interfering with the proliferation
capacity by cell contact-mediated inhibition. Accordingly, we performed additional experi-
ments using a lower cell seeding density and continuous ECIS impedance measurement
over seven days, focusing on a concentration of 100 µg/mL. As depicted in Figure 6c,d,
the impedance as an indicator of cell layer confluency showed a significant reduction for
all tested Fucus extracts after seven days. Thus, tested Fucus extracts impaired the MSC
proliferation using a higher concentration of 100 µg/mL and a lower cell density.
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Figure 6. Effect of fucoidan on cell proliferation depicting the DNA content of MSC mono-cultures at (a) 1 and (b) 10 µg/mL
fucoidan/heparin treatment and (c,d) impedance measurement for MSC (seeded at a density of 5000 cells/cm2) detected by
ECIS at 100 µg/mL treatment. One-way ANOVA, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, n = 3.
2.7. Impact of Fucus Extracts on the Osteogenic Activity in Human Mesenchymal Stem Cells
To evaluate if Fucus extracts from different species modulate the osteogenic differ-
entiation of MSC, we determined the expression and activity of the early osteogenic
differentiation marker alkaline phosphatase and the calcification process indicating the
later stages of osteogenic differentiation. The gene expression of the early osteogenic
marker alkaline phosphatase (ALP) was found to be significantly downregulated on day 7
for all the fucoidan treatments except for Fs2 (Figure 7a). On day 14, the ALP activity was
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lower in fucoidan-treated cells than in the untreated group, similar to PCR data, but no
significant effect was observed (Figure 7b).
Figure 7. Relative gene expression for the osteogenic markers (a) ALP and (c) osteocalcin evaluated
by semi-quantitative RT-PCR for MSC mono-cultures treated with fucoidan extracts and heparin at a
concentration of 100 µg/mL on day 7; (b) ALP activity for the MSC mono-cultures with 100 µg/mL
extracts treatment on day 14, and (d) the osteogenic activity determined by Alizarin Red staining
for MSCs treated with 100 µg/mL extracts on day 14. One-way ANOVA, * p < 0.05, ** p < 0.01,
*** p < 0.001, **** p < 0.0001, n = 3.
As shown in Figure 7d, the calcification level determined by Alizarin Red staining
showed a significant reduction when MSCs were treated with Fvc, Fvp, Fv2, and Fs2.
Other extracts had a similar but not significant effect on the calcification level, and results
reflected widely data by PCR for osteocalcin (Figure 7c).
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2.8. Effects of Fucus Extracts on Regulatory Molecules for Angiogenesis in MSC
As bioactive compounds with the potential to modulate angiogenesis in the bone,
we investigated the effect of different fucoidan doses on key molecules such as vascular
endothelial growth factor (VEGF) and angiopoietin 1 (ANG-1) expressed by MSC. We
also studied the effect of fucoidan on stromal derived factor-1 (SDF-1), a chemokine that
regulates the recruitment of various cell types including stem cells, osteoclast precursor
cells, and immune-cells [22,23]. In previous studies, we found MSC to be the main producer
of VEGF, SDF-1, and ANG-1 [24,25]. After fucoidan treatment, all tested extracts reduced
the VEGF amount found in the supernatant of MSC (day 7). While Fvc, Fvp, Fv1, Fv2,
and Fv3 caused a significant VEGF reduction at 10 µg/mL, Fs1, Fs2, and Fe treatment
already lowered VEGF levels at the lowest tested concentration of 1 µg/mL. To achieve a
significant reduction of SDF-1 levels in MSC, a concentration of 10 µg/mL was necessary
for all tested extracts. Further, treatment with 10 µg/mL was necessary to reduce ANG-1
levels in MSC, with exception of Fe and Fs1, which significantly lowered ANG-1 already
at the smallest tested concentration of 1 µg/mL. Additional data regarding the gene
expression for angiogenic regulator molecules in OEC and MSC are depicted in Figure
S4 (supplements). Overall, the protein data suggest a clear dose-dependent effect for all
tested extracts and tested target molecules for MSC, although the concentrations required
to lower the levels of these growth factors slightly varied depending on the extracts or the
target molecule.
2.9. Influence of Selected Fucus Extracts on the Formation of Vascular Structures in MSC–OEC
Co-Culture Models
To analyze the effect of fucoidan treatment on the formation of vascular structures on
the functional level, we performed co-culture experiments that allow a direct interaction
of endothelial cells and bone forming cells, resulting in the formation of microvessel-like
structures. For this, OEC were co-cultivated with MSC as well as with the osteosarcoma
cell line MG63 to model vascularization processes in both bone formation and bone tumors.
Co-cultures were treated with selected Fucus extracts Fs1 and Fs2. In addition, Fvc
was used as reference as it displayed antiangiogenic properties in our previous study [4].
Fs1 and Fs2 were selected due to a high tolerability for both cell types (Figures 1 and 5),
combined with a low inflammatory potential in endothelial cells but a high effectivity to
modulate angiogenic molecules in OEC and MSC (Figures 4 and 8). Both concentrations
(10 and 100 µg/mL) of Fs1 and Fs2 lowered the number of vascular structures in both types
of co-cultures, but results are depicted only for the lower concentration (Figure 9). These
findings indicate an antiangiogenic effect of the extracts in accordance with their effects on
the growth factors VEGF, ANG-1 and ANG-2, guiding the formation of vascular structures.
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Figure 8. The relative amount of angiogenic growth factors: (a) vascular endothelial growth factor (VEGF), (b) stromal
derived factor-1 (SDF-1), and (c) angiopoietin 1 (ANG-1) in supernatant of MSC mono-cultures treated with 100 µg/mL
fucoidan/heparin on day 7, measured with enzyme-linked immunosorbent assay. One-way ANOVA, * p < 0.05, ** p < 0.01,
*** p < 0.001, **** p < 0.0001, n = 3.
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Figure 9. Confocal laser scanning microscopy for: MSC/OEC co-cultures on day 7 for control (a) and
10 µg/mL treatment of Fvc (b), Fs1 (c), and Fs2 (d); MG63/OEC co-cultures on day 7 for control (e)
and 10 µg/mL treatment of Fvc (f), Fs1 (g), and Fs2 (h). Endothelial marker VE-cadherin is depicted
in green, and nuclei are depicted in blue. The scale bar represents 100 µm.
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3. Discussion
Biomedical applications of compounds require solid data on biological activity and
safety, including clear structure–function relationships. Crude fucoidan extracts are multi-
component products and their complex composition impede the structure–function corre-
lations. As numerous studies have shown, the biological properties of fucoidans are highly
dependent on their chemical properties, which in turn are tightly related to the species as
well as the way they are harvested and extracted [11,26–28]. In this study, we evaluated six
crude fucoidan extracts from three Fucus species obtained by different extraction methods.
We compared them in terms of several aspects, starting with their chemical properties
depending on the extraction procedure and species but mainly focusing on their impact
on different cell types involved in bone formation and vascularization or the associated
mediator molecules. The study provides a comprehensive data set by combining chemical
characterization and biological assessment down to the cellular and molecular level using
primary human cells.
Although this study does not specifically focus on a comparison of extraction methods,
we noticed that extraction with 100 mM hydrochloric acid (HCl) led to pronounced loss
of fucose and sulfate groups (Table 1). These data are in accordance with the literature,
indicating that HCL-based extraction and higher acid concentrations interfere with the
fucose or sulfate content or provoke degradation of polysaccharides in the extracts [29,30].
In contrast, the three extracts obtained by short-term heating with demineralized
water and diluted (10 mM) sulfuric acid had higher fucose contents and DS values. The
association between fucose content and DS was shown to be due primarily to the fact that
the fucose units in fucoidans are sulfated [31]. In line with previous results [27,28], the
treatment at 120 and 100 ◦C, respectively, was associated with degradation of the fucoidans,
but not desulfation.
The tested fucoidan extracts largely varied in their mean MW as well as MW distri-
butions (Table 1 andTable S1). With mean MW ranging between 84 kDa and 730 kDa and
their wide MW ranges, they represent high molecular weight fucoidans in accordance with
the common consent from literature. Although MW represents an important parameter for
the biological activities of fucoidans [27,28], any conclusions regarding the impact of MW
are limited by the very high polydisperity of the tested fucoidan extracts, which was even
higher when HCl and sulfuric acid were used for extraction.
Products of natural origin may be contaminated with endotoxins. Therefore, we
further analyzed the endotoxin content of the tested fucoidan extracts. Since endotoxins
may cause inflammatory and immunological reactions [32,33], parentally applied medical
products or materials getting in contact with blood must be endotoxin-free. Especially
endothelial cells react highly sensitively toward endotoxins, with release of inflamma-
tory molecules, changes in barrier, and increased angiogenic activity [34,35]. Thus, the
evaluation of endotoxins was essential to avoid any artificial results and to exclude poten-
tial influences by endotoxins on the investigated parameters described in the following
sections.
Fucoidan extracts have differential effects on individual cell types, and their influences
further vary in tumor-derived cell lines compared with primary cells [4]. In agreement with
previous data from our group [4], endothelial cells compared with MSC tolerated higher
doses of the tested fucoidans up to 200 µg/mL. Nevertheless, some of the tested extracts
influenced the barrier and caused an increased secretion of IL-6, one of the main mediator
molecules in inflammatory processes in endothelial cells [20]. If these observations correlate
with the fucus species, the individual composition of the extracts or their extraction method
cannot be finally clarified in this study. Nevertheless, such influences might correlate with
the higher molecular weight, as indicated by the data for Fv1 and Fv2 in this study.
Further, inflammation and changes in the barrier may also influence the formation of
vascular structures [36]. Thus, these extracts were excluded in the functional assessment of
angiogenesis in the co-cultures.
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In comparison with endothelial cells, MSC were more sensitive in response to fucoidan
treatment. MTS values as indicators of metabolic activity were reduced at concentrations
of 10 µg/mL or higher for the Fucus vesiculosus extracts. Similar results were reported
before by our group for commercially available crude Fucus vesciculosus extracts. Although
the extracts Fs1, Fs2, and Fe did not reduce the metabolic activity in MSC, all tested
extracts impaired the proliferation of MSC at 100 µg/mL, indicated by ECIS measurement.
We presently speculate that the reduced proliferation observed at higher doses might
be associated with the auto-regulatory function of the growth factor VEGF. Previous
publications have demonstrated an autocrine influence of VEGF on MSC proliferation and
differentiation [37–39]. Thus, reduced VEGF levels, discussed in more detail in the next
sections, may be responsible for impaired proliferation and metabolic activity of MSC.
Fucoidans have been reported to influence vascularization processes [40], although
the detailed mechanisms are still not elucidated in detail [41] and even contradictory effects
were described in the literature [42]. In our study, the influence of fucoidans on growth
factors in the cell culture supernatants was determined using ELISA. All fucoidan extracts
significantly lowered the concentrations of VEGF in the supernatants of MSC monocultures
in a dose-dependent manner. These data indicate a reliable biological effect even in the
context of a primary cell system for the bone, including donor-related variations in growth
factor expression or non-homogeneous cell populations in MSC. For the extracts Fs1, Fs2,
and Fe, a significant impact was already observed at 1 µg/mL, whereas for other extracts
concentrations of 10 µg/mL were needed to achieve a significant reduction. For ANG-1,
comparable significant effects were observed at the lowest tested dose, confirming the
higher effectivity of Fs1 and Fe.
Interestingly, Fs1 and Fe were the extracts with the highest DS, followed by Fv3 and
Fs2, potentially responsible for the impact on the VEGF observed at the lowest tested dose.
The DS was shown to be an important factor for the pharmacological activities of fucoidans.
In our previous study fucose and DS enriched fractions gained from Fucus distichus subsp.
evanescence resulted in lower VEGF levels and increased the antiangiogenic properties of
these fractions in comparison with their crude counterparts[15]. Thus, high fucose and DS
seem to be key features for lowering VEGF levels, resulting in antiangiogenic effects.
Beyond VEGF, which is mainly produced by MSC, ANG-2 produced by endothelial
cells [24] is a critical co-factor guiding angiogenesis. The combination of VEGF and ANG-2
is needed to induce new vessel formation and angiogenic activation of endothelial cells [43].
In this study, all tested fucoidans besides Fe reduced ANG-2 produced by endothelial
cells. Furthermore, ANG-2 is a factor in inflammation and tumor metastasis [44]. In
addition, the chemokine SDF-1, involved in stem- and inflammatory cell recruitment [45],
vascularization [46], and osteosarcoma metastasis [47,48], was consistently reduced by all
tested extracts.
Although effects on the angiogenic mediator are important parameters to indicate
a therapeutical potential of fucoidans to control angiogenesis, vascularization processes
are highly complex and dynamic and underlie a spatial and temporal control of multiple
factors. Accordingly, evaluation of pro- or antiangiogenic properties of fucoidans should
be supported by functional evaluation in a defined physiological context. For functional
evaluation, we have chosen two co-culture models, allowing direct interactions between
endothelial cells and bone cells [24,49]. In one, we used MSC to model bone formation;
in the other one, we used the tumor cell line MG63 to model osteosarcoma. The selected
extracts for these experiments, Fs1 and Fs2, showed antiangiogenic properties in both co-
culture systems. The results were similar to previous reports using commercially available
high molecular weight fucoidan [4]. The antiangiogenic effect in this present and in
our previous study correlated with reduced concentrations of the growth factors VEGF,
ANG-2, and ANG-1 in a very consistent and dose-dependent manner. All tested extracts
resembled mainly HMW fucoidan but with variations in the molecular weight. A recent
study by Gupta et al. showed antiproliferative effects of fucoidans on the osteosarcoma
cell line MG63 depending on the species and molecular weight, resulting in the G1 arrest
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for high and medium molecular weight fucoidan treated cells [50]. Although MSC used
in this present study proliferate more slowly compared to MG63, we observed to some
extent similar effects for MSC, indicating that high molecular weight fucoidan may impair
osteogenic cells’ metabolic activity and proliferation.
4. Materials and Methods
4.1. Fucoidan Extraction
Fucus vesiculosus (Fv), Fucus serratus (Fs), and Fucus subs. evanescens (Fe) were har-
vested in Kiel, Germany, and used for the extraction of crude fucoidan as described in
detail by Ptak et al. [51]. All seaweeds were initially soaked in 85% ethanol solution
overnight, followed by a wash with acetone. After drying, the fucoidans were extracted.
The extracts Fs1 and Fs2 were extracted from Fucus serratus (harvested in October) with
10 mM sulfuric acid at 100 ◦C for 30 min (Fs1) and 100 mM hydrochloric acid at 80 ◦C
(Fs2) for 30 min, respectively, using microwave-assisted extraction. The extracts were
subsequently neutralized with 1 M sodium hydroxide and transferred to a conical tube.
A strong solution (35%) of calcium chloride was added to the extracts to reach a final
concentration of 1% in each tube. The extracts were then centrifuged (30 min at 4 ◦C),
and the supernatant was transferred to a new conical tube. Ethanol (96%) was added
to each tube for a final concentration of 40%. After the addition of ethanol, the extracts
were centrifuged, and the supernatant was recovered. A final addition of ethanol was
applied for a concentration of 70%, and the extracts were centrifuged a final time. The
pellet was recovered and washed with ethanol and acetone and left to dry. After drying,
the pellet was solubilized in demineralized water and dialyzed (MWCO = 12–14 kDa) until
the conductivity of the surrounding water no longer increased. After dialysis, the extracts
were freeze-dried and analyzed for chemical characterizations. For the following extracts,
purification was performed as previously described unless stated otherwise. The crude
fucoidan extract Fv1 was prepared by soaking F. vesiculosus (harvested in July) in 100 mM
hydrochloric acid for 24 h, followed by neutralization with 1 M sodium hydroxide. Fv2
was similarly prepared as Fv1 from Fucus vesiculosus (harvested in October); however, the
soaking and decanting step was repeated twice for three soaking steps in total. Fv3 was
extracted from Fucus vesiculosus (harvested in October) with demineralized water at 120 ◦C
for 30 min using microwave-assisted extraction. Fe was prepared from Fucus distichus
subsp. evanescens (in July) and extracted similarly to Fv3. Specification of extracts and
isolation are summarized in Table 3.




Fv1 F. vesiculosus July 100 mM hydrochloric acid RT 24 h
Fv2 F. vesiculosus October 100 mM hydrochloric acid × 3 RT 24 h
Fv3 F. vesiculosus October demineralized water * 120 ◦C 30 min
Fe F. evanescens July demineralized water * 120 ◦C 30 min
Fs1 F. serratus October 10 mM sulfuric acid * 100 ◦C 30 min
Fs2 F. serratus October 100 mM hydrochloric acid * 80 ◦C 30 min
Ex.: extracts; * microwave assisted; RT: room temperature.
4.2. Chemical Characterization
4.2.1. Elemental Analysis
The content of hydrogen, carbon, nitrogen, and sulfur was determined by elemental
analysis as described previously [16]. The degree of sulfation (DS, number of sulfate group
per monosaccharide) was calculated using the determined sulfur content (%) [16]. The
total protein content was estimated by multiplying the nitrogen content (%) by 6.25.
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4.2.2. Monosaccharide Composition by GLC
To determine the neutral monosaccharide composition, acetylation analysis of the
fucoidans was performed as previously reported [16]. Briefly, the fucoidans were hy-
drolyzed using 2M TFA [52], converted into alditol acetate derivatives (AA) by reduction
and acetylation [18]. The AA derivatives were separated by gas-liquid chromatography
(GLC), and the percentage of the respective AA was calculated.
4.2.3. SEC-MALS-VIS Analysis
The molecular mass of the fucoidans was measured by size-exclusion chromatog-
raphy (SEC) using an HPLC system equipped with multi-angle light scattering (MALS),
viscometry (VIS) and refractive index (RI) detectors. The separation of the samples was
achieved using an Agilent 1260 series quaternary pump with an OHPak LB-806M (8.0
mmID X 300 mmL; ShodexTM, Agilent, Waldbronn, Germany). The column outlet was
connected to HELEOS-II MALS photometer (Wyatt Technology, Dernbach, Germany),
followed by a ViscoStar III differential viscometer and an Optilab T-rEX differential refrac-
tometer (Wyatt Technology, Dernbach, Germany). The eluent was PBS buffer solution (50
mM Na2HPO4-NaH2PO4 and 150 mM NaCl, pH 7.0), and the flow rate was 0.7 mL/min.
The fucoidan samples (2 mg/mL) were filtered (0.45 µm) before injection. The injection
volume was 100 µL. The used dn/dc was 0.150 as previously described for fucoidans [17].
The data were collected and processed using the Astra (v.7.3.2) software (Wyatt Technology,
Dernbach, Germany).
4.3. EndoLISA® Endotoxicity Assay
Freeze-dried fucoidan extracts were solubilized at a concentration of 5 mg/mL in
water and sterilized by sterile filtration through 0.2 µm filter. Only fully soluble extracts
were used for the biological assessment.
EndoLISA® kit (Hyglos, Germany) was used to determine the endotoxin content of
the fucoidan samples according to the manufacturer’s instruction. The fucoidan samples
were diluted to 100 µg/mL. Both samples and standards were prepared in duplicates and
applied to the pre-treated lipopolysaccharide (LPS)-specific phage-binding plate, followed
by adding the binding buffer and incubation overnight (18 h mixing at 450 rpm and 37 ◦C).
After 3 washing steps to remove the matrix substances, assay reagent was applied. The
fluorescence after 90 min was read at 380/445 nm of excitation/emission wavelength, and
the relative fluorescence unit was calculated. The endotoxin content of fucoidan samples
was calculated from a standard curve.
4.4. Ethical Approval for the Use of Human Cells
The MSC and OEC were isolated from human tissues. The use of human tissue and
cells was approved by the local ethical advisory boards, including the consent from the
individual donors.
4.5. Isolation and Culture of Human Mesenchymal Stem Cells (MSCs)
Human mesenchymal stem cells (MSCs) were isolated from bone tissue fragments
from femoral head as described by our group before [24,25]. In brief, bone marrow cells
from cancellous bone structures were collected by washing bone fragments in tissue
buffer (Medium 199), GlutaMaxTM (Gibco, Darmstadt, Germany), 20% fetal bovine serum
(FBS) (Sigma, Taufkirchen, Germany), 1% penicillin/streptomycin (Pen/Strep) (Biochrom,
Berlin, Germany), 1% fungizone (Biozol, Eching, Germany), and 1% ciprobay (FRESENIUS
KABI, Bad Homburg, Germany). After centrifugation, cells were plated at a density
of 2 × 106 cells/cm2 to collagen type I (Corning, Bedford, MA, USA) coated flasks in
Dulbecco’s Medium Essential Medium (DMEM)/Ham F-12 (Biochrom, Berlin, Germany)
supplemented with 20% FBS and 1% Pen/Strep. Cells from passage 2 on cells were
cultivated in osteogenic differentiation medium (ODM). ODM consisted of DMEM/Ham
F-12, 0.1 µM dexamethasone (Sigma-Aldrich, St. Louis, MO, USA), 10 mM β-glycerol
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phosphate (Sigma-Aldrich, St. Louis, MO, USA), 50 µM ascorbic acid-2-phosphate (Sigma-
Aldrich, St. Louis, MO, USA), 10% FBS, and 1% Pen/Strep. Cells were maintained for
at least 2 weeks in ODM to obtain MSC with an osteogenic phenotype. Cells used in the
presented study were in passage from 2 to 4 and were gained from MSC donors at the age
of 78 (m), 69 (f), and 48 (m).
4.6. Isolation and Culture of Human Outgrowth Endothelial Cells (OECs)
Human outgrowth endothelial cells (OECs) from peripheral blood were isolated
and cultured by the methods described previously [53,54]. Briefly, human mononuclear
cells were isolated from buffy coat by gradient centrifugation using Biocoll (Biochrom,
Berlin, Germany). After being resuspended in Endothelial Cell Growth Medium 2 (ECGM-
2) (PromoCell, Heidelberg, Germany) with supplements from the kit, 5% FBS, and 1%
Pen/Strep, cells were seeded in collagen type I coated 24-well plates at a density of 2.6 ×
106 cells/cm2 and further sub-cultured to new collagen type I coated 24-well plates after 7
days. Within 2–3 weeks, cobblestone-like OECs appeared, and cells were expanded for the
experiments. Cells (passage 6–7) in the presented study were from buffy coat donors at the
age of 59 (f), 25 (f), 20 (f), and 66 (m).
4.7. Cell Seeding and Fucoidan Treatment of Individual Cell Types
MSC or OEC were seeded at a density of 40.000 cells/cm2 to multi-well plates coated
with fibronectin for OEC monocultures and with collagen I (Corning, Badford, MA, USA)
for MSC mono-cultures (Millipore, Temecula, CA, USA).
MSCs were cultured in ODM; OECs were maintained in ECGM-2. One day after seed-
ing, the cells were treated with the fucoidan extracts described in Table 1 and commercial
fucoidan extracts (Sigma, F5631-1G and F8190, Sigma, Taufkirchen, Germany) as well as
heparin (physico-chemical analysis, Y0001282) at different concentrations in cell medium.
The treatment was exchanged every 3 days along with medium exchange.
4.8. MTS Cell Metabolic Activity Assay
The metabolic activity of cells was determined with CellTiter 96® AQueous One
Solution Cell Proliferation Assay (Promega, Madison, WI, USA). MSC or OECs were seeded
on 96-well plates at a density of 40.000 cells/cm2. Cells were treated with concentrations of
1, 10, 50, 100, and 200 µg/mL fucoidan extracts and heparin. To characterize cell metabolic
activity, the cells were incubated with MTS solution (1:6 diluted in medium) at 37 ◦C for
2 h. The absorbance at 490 nm was measured using a microplate reader. The cellular
metabolic activity was calculated relative to the control group (100%) after subtracting the
background absorbance.
4.9. LDH Cytotoxicity Assay
To determine the cytotoxicity of fucoidan extracts and heparin in MSC or OEC at dif-
ferent concentrations, we performed LDH (lactate dehydrogenase) assay (Thermo Scientific,
Rockford, IL, USA) at 24, 72, and 168 h after treatment using the cell culture supernatants
as described in the previous section and the protocol according to manufacturer. First, the
maximum LDH control was prepared by adding lysis buffer to cells in technical triplicates.
After 45 min incubation at 37 ◦C, the supernatants were transferred to a 96-well plate
and reaction mixture was added. After 30 min incubation at room temperature, the stop
solution was applied, and the OD was measured at 490 and 680 nm on a plate reader. The
absorbance at 680 nm was subtracted from the absorbance at 490 nm, and the cytotoxicity
was calculated as a percentage relative to the maximum LDH activity control.
4.10. Immunofluorescence Staining and Visualization of OECs
OECs were seeded on fibronectin coated Thermanox coverslips (Thermo scientific,
Rochester, NY, USA) in 24-well plates at a density of 40.000 cells/cm2. OECs were treated
with fucoidan extracts for 7 days and fixed with 4% paraformaldehyde in phosphate
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buffered saline (PBS) (Affymetrix, Cleveland, OH, USA), followed by 3 times of a 5 min
wash with PBS and 10 min permeabilization with 0.5% Triton® X-100. Cells were incubated
with VE-cadherin (R&D, Minneapolis, MN, USA) antibody (1:50 diluted in PBS with 1%
bovine serum albumin (BSA)) for 1.5 h and with the secondary antibody (1% BSA in PBS)
for 30 min after being washed with PBS 3 times for 5 min. Cells were incubated for 10
min with Hoechst (2 µg/mL in PBS). The cells on Thermanox coverslips were mounted
with Fluoromount Aqueous Mounting Medium (Sigma-Aldrich, St. Louis, MO, USA) for
subsequent visualization with confocal laser scanning microscopy (CLSM, LSM 510 Meta,
Zeiss, Oberkochen, Germany).
4.11. Electrical Cell-Substrate Impedance Sensing (ECIS) for MSC and OEC
OECs were seeded to 8W10E slides coated with fibronectin (Applied BioPhysics, Troy,
NY, USA) at a density of 40.000 cells/cm2 in ECGM-2 medium. Then, cells were cultured for
3 days in ECGM-2 to reach 100% confluence and to establish a tight cell barrier before the
cells were treated for 7 days with fucoidan and heparin while monitoring the impedance.
The impedance as a percentage in relation to the control was analyzed.
For MSC, cells were seeded at a lower density of 5000 cells/cm2 on the collagen I
coated 8W10E slides in order to monitor the impedance as an indicator of MSC proliferation.
The cells were treated the second day after seeding. The impedance values were recorded
for 7 days with ECIS (applied biophysics, Troy, NY, USA). The mean values were calculated
after subtracting blank values for each condition.
4.12. Quantification of DNA Content
The double-stranded DNA content of MSC mono-cultures in 24-well plates was de-
termined to analyze the impact of fucoidans on the cellular proliferation. DNA content
was determined with Quant-iT PicoGreen dsDNA assay kit (Molecular probes, Eugene,
OR, USA). To prepare the DNA aqueous solution, cells were trypsinized in 24-well plates.
After centrifuging the cell suspension for 5 min at 2000 g, cell pellets were collected and
resuspended in 1 mL deionized water. Cell membranes were ruptured to release DNA by
three freeze–thaw cycles and two 15 s sonications. Samples and standards were prepared
in triplicates. DNA amount was determined by measuring the fluorescence using a mi-
croplate reader (TECAN, Maennedorf, Switzerland) at 485/535 nm of excitation/emission
wavelength.
4.13. Gene Expression Analysis
Total RNA isolation from MSCs and OECs was performed according to the manu-
facturer’s protocol using Total RNA Kit (VWR peqlab, Erlangen, Germany). The RNA
concentration was determined with a NanoDrop (Thermo Fisher, Erlangen, Germany).
Then, 1 µg of total RNA per sample was transcribed to cDNA with high capacity RNA-to-
cDNA Kit (Applied Biosystems, Carlsbad, CA, USA). PCR was performed using primers as
indicated in Table 4 using RPL13a as an internal control gene. Quantitative real-time PCR
was carried out using a total volume of 20 µL for each reaction. The mastermix contained
SYBR® Select Master Mix (Applied Biosystems, Austin, TX, USA), cDNA QuantiTect®
Primer Assay (Qiagen, Hilden, Germany), RNase free water (Qiagen), and 3.2 µL cDNA.
The mixtures were preheated to 50 ◦C for 20 min and 95 ◦C for 20 min, followed by 40
cycles of 95 ◦C for 15 s (step 1) and 60 ◦C for 60 s (step 2). The relative gene expression was
calculated with the ∆∆cT method. Fucoidan or heparin treated groups were normalized to
untreated controls.
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Table 4. Primer List for individual molecules and internal housekeeping gene (RPL13A).
Gene Name Primer Assay Catalogue No.
ALP Hs_ALPL_1_SG QuantiTect Primer Assay QT00012957
Angiopoietin 1 Hs_ANGPT1_1_SG QuantiTect Primer Assay QT00046865
Angiopoietin 2 Hs_ANGPT2_1_SG QuantiTect Primer Assay QT00100947
Osteocalcin Hs_BGLAP_1_SG QuantiTect Primer Assay QT00232771
ICAM Hs_ICAM1_1_SG QuantiTect Primer Assay QT00074900
IL-6 Hs_IL6_1_SG QuantiTect Primer Assay QT00083720
SDF-1 Hs_CXCL12_1_SG QuantiTect Primer Assay QT00087591
VCAM-1 Hs_VCAM1_1_SG QuantiTect Primer Assay QT00018347
VEGF Hs_VEGFA_2_SG QuantiTech Primer Assay QT01036861
RPL13A Hs_RPL13A_1_SG QuantiTect Primer Assay QT00089915
4.14. Enzyme Linked Immunosorbent Assay (ELISA)
To examine the protein levels in supernatant, the sample supernatants were collected
to perform IL-6, ICAM-1, and angiopoietin 2 ELISA for OEC mono-cultures and, respec-
tively, VEGF, SDF-1, and angiopoietin 1 ELISA for MSC mono-cultures using the Duo-Set
ELISA Development kits (R&D, Minneapolis, MN, USA) according to the manufacturer’s
protocols. The optical absorbance was detected by a microplate reader at 450 nm with a
reference wavelength of 560 nm. The protein levels were presented relative to the controls.
4.15. Quantitative Analysis of Osteogenesis
To quantitatively determine the influence of 100 µg/mL fucoidan on the calcification
level in MSC mono-cultures at day 14, 1 mL of 40 mM Alizarin Red S Stain Solution (Milli-
pore, Billerica, MA, USA) was applied to 4% PFA (paraformaldehyde) fixed cell monolayers
in 24-well plates and incubated for 30 min. Cells were washed with distilled water until the
wash solution became colorless and were incubated with 10% (w/v) cetylpyridinium chlo-
ride (CPC) (Roth, Karlsruhe, Germany) overnight to extract the Alizarin Red. Extracts were
added to a 96-well plate containing standards prepared as well in 10% CPC. Absorbance of
the samples was measured at a wavelength of 560 nm in a microplate reader.
4.16. Alkaline Phosphatase (ALP) Activity Assay
To measure the impact of fucoidan in MSC mono-cultures on ALP activity, the su-
pernatant was collected 7 days after treating with 1, 10, and 100 µg/mL fucoidan, and an
alkaline phosphatase assessment was performed according to the manufacturer’s protocol
from the kit (Abcam, Germany). In brief, samples and standards were prepared in trip-
licates in 96-well plates for ALP reaction with pNPP Solution. Stop solution was added
to the control wells before starting the ALP reaction to determine the background values.
After 60 min incubation, the reaction in samples was stopped by stop solution, and the OD
value was measured at 405 nm with a microplate reader. The values were calculated after
background subtraction and are presented relative to the control.
4.17. Co-Cultures
MSC or the osteosarcoma cell line MG63 (ATCC, Wesel, Germany) were seeded at a
density of 40.000 cells/cm2 on collagen I (Corning, Badford, MA, USA) coated Thermanox
coverslips in 24-well plates. Then, OECs were added to MSC or MG63 cultures the second
day in the same seeding density. The co-cultures were maintained in ECGM-2 and treated
with 10 or 100 µg/mL fucoidan extracts (Fvc, Fs1, and Fs2) one day after seeding OECs.
Cells were fixed with 4% PFA and stained on day 7 as described in 2.10.
4.18. Statistical Analysis
All experiments mentioned above were carried out with cells from at least 3 different
donors. The statistical significance of the results was assessed with unpaired one-way
ANOVA or two-way ANOVA using Graphpad Prism 7. As indicated in the corresponding
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result sections, p < 0.05 (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001) was considered
as statistically significant.
5. Conclusions
In conclusion, crude fucoidan extracts isolated from different fucus species represented
mixtures of HMW fucoidans. Tested extracts consistently lowered important molecular
mediators involved in angiogenesis in endothelial cells and MSC in vitro, but the doses
needed to achieve a significant reduction differed amongst the extracts. In this context, the
degree of sulfation seems to be a critical factor. The antiangiogenic effect was confirmed at
the functional level in in vitro models mimicking vascularization in bone repair or bone
tumors. Thus, HMW might be more useful in osteosarcoma treatment and less suitable for
bone regeneration—something to be tested in in vivo models in the future.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/md19040194/s1. Figure S1: Molecular mass-versus-elution time plots for (A) three fucoidans
from F. vesiculosus (Fv1, Fv2 and Fv3) and (B) two fucoidans from F. serratus (Fs1 and Fs2) as well as
one from F. distichus subsp. evanescens (Fe). RI chromatogram is overlayed in all plots, Figure S2: (A)
Differential molecular mass distribution and (B) cumulative molecularar mass distribution analyses
of three fucoidans from F. vesiculosus (Fv1, Fv2 and Fv3), two fucoidans from F. serratus (Fs1 and
Fs2), and one from F. distichus subsp. evanescens (Fe). Differential distribution plot is the visual
representatio of multimodal (more than one peak) or monomodal composition of the sample, while
the cumulative distribution plot shows the weight fraction of certain molecular mass range, Figure S3.
Relative gene expression for the inflammatory response relevant molecules a) IL-6, b) ICAM-1 and c)
VCAM evaluated by semi-quantitative RT-PCR for mono-cultures of OEC treated with 100 µg/mL
fucoidan on day 7. 1-way ANOVA. * p < 0.05, **p < 0.01. n = 3, Figure S4. Relative gene expression
for the angiogenic molecules a) VEGF, b) SDF-1, c) ANGPT-1 for MSCs and d) ANGPT-2 for OECs
with 100 µg/mL fucoidan and Heparin treatment evaluated by semi-quantitative RT-PCR on day 7.
1-way ANOVA. *p < 0.05, ** p < 0.01. n = 3.
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